Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update
05 août 2020 16h15 HE
|
ARCA biopharma, Inc.
AB201 being developed as a potential treatment for COVID-19 and other RNA virus associated diseasesARCA anticipates filing an IND for AB201 in Q3 2020 and initiating Phase 2 clinical testing in Q4...
SARS-CoV-2 Cell Entry Mechanisms in Intact Human Heart Published in JACC: Basic to Translational Science by University of Colorado Anschutz Medical Campus and ARCA biopharma Investigators
07 juil. 2020 08h30 HE
|
ARCA biopharma, Inc.
Integrin A5 may be a new target for intervening in the cell infectious processFindings may lead to the development of precision therapeutic approaches to prevent SARS-CoV-2-cell entry while preserving...
ARCA biopharma Announces Closing of $6.1 Million Registered Direct Offering
03 juin 2020 09h55 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., June 03, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically...
ARCA Biopharma Announces $9.4 Million Registered Direct Offering
01 juin 2020 08h20 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., June 01, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically...
ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy
28 mai 2020 08h00 HE
|
ARCA biopharma, Inc.
AB201 (rNAPc2) is being developed as a potential treatment for COVID Associated Coagulopathy, a condition characterized by abnormal blood clotting in patients with COVID-19Previous safety data in more...
Clinical Data Evaluating Gencaro for the Treatment of Atrial Fibrillation in Heart Failure Patients Featured in Three Presentations at the 2020 Heart Rhythm Scientific Sessions
07 mai 2020 08h30 HE
|
ARCA biopharma, Inc.
New data provide additional evidence of efficacy for Gencaro compared to active control in a pharmacogenetically-defined HF population at risk for AF recurrence ° 26% reduction in total time spent...
ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update
06 mai 2020 16h30 HE
|
ARCA biopharma, Inc.
U.S. FDA Special Protocol Assessment agreement for PRECISION-AF, a single pivotal Phase 3 clinical trial of genetically targeted GencaroPRECISION-AF trial to evaluate Gencaro as a potential treatment...
ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update
18 févr. 2020 16h30 HE
|
ARCA biopharma, Inc.
U.S. FDA Special Protocol Assessment agreement for a single pivotal Phase 3 clinical trial (PRECISION-AF) of genetically-targeted GencaroPRECISION-AF clinical trial initiation anticipated fourth...
ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update
06 nov. 2019 16h10 HE
|
ARCA biopharma, Inc.
PRECISION-AF pivotal Phase 3 clinical trial initiation anticipated first quarter of 2020Trial to examine atrial fibrillation in a heart failure population for which there are no FDA indicated drug...
ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium
12 sept. 2019 08h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Sept. 12, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...